AU2019279001B2 - Compositions and methods for detection of traumatic brain injury - Google Patents

Compositions and methods for detection of traumatic brain injury

Info

Publication number
AU2019279001B2
AU2019279001B2 AU2019279001A AU2019279001A AU2019279001B2 AU 2019279001 B2 AU2019279001 B2 AU 2019279001B2 AU 2019279001 A AU2019279001 A AU 2019279001A AU 2019279001 A AU2019279001 A AU 2019279001A AU 2019279001 B2 AU2019279001 B2 AU 2019279001B2
Authority
AU
Australia
Prior art keywords
carbons
alkyl
heteroarylene
heterocycloalkyl
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019279001A
Other languages
English (en)
Other versions
AU2019279001A1 (en
Inventor
Lyndsay M. RANDOLPH
Suhail RASOOL
Stella SARRAF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amydis Inc
Original Assignee
Amydis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amydis Inc filed Critical Amydis Inc
Publication of AU2019279001A1 publication Critical patent/AU2019279001A1/en
Application granted granted Critical
Publication of AU2019279001B2 publication Critical patent/AU2019279001B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
AU2019279001A 2018-05-31 2019-05-31 Compositions and methods for detection of traumatic brain injury Active AU2019279001B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862678900P 2018-05-31 2018-05-31
US62/678,900 2018-05-31
US201862733025P 2018-09-18 2018-09-18
US62/733,025 2018-09-18
PCT/US2019/034977 WO2019232422A1 (en) 2018-05-31 2019-05-31 Compositions and methods for detection of traumatic brain injury

Publications (2)

Publication Number Publication Date
AU2019279001A1 AU2019279001A1 (en) 2020-12-03
AU2019279001B2 true AU2019279001B2 (en) 2025-11-27

Family

ID=68697319

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019279001A Active AU2019279001B2 (en) 2018-05-31 2019-05-31 Compositions and methods for detection of traumatic brain injury

Country Status (8)

Country Link
US (2) US12478693B2 (cg-RX-API-DMAC7.html)
EP (1) EP3803416A4 (cg-RX-API-DMAC7.html)
JP (3) JP7381500B2 (cg-RX-API-DMAC7.html)
CN (2) CN112424606B9 (cg-RX-API-DMAC7.html)
AU (1) AU2019279001B2 (cg-RX-API-DMAC7.html)
CA (1) CA3100700A1 (cg-RX-API-DMAC7.html)
MA (1) MA52796A (cg-RX-API-DMAC7.html)
WO (1) WO2019232422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019372432B2 (en) * 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders
JP7591040B2 (ja) * 2019-09-18 2024-11-27 アミディス, インコーポレイテッド リン酸化タウタンパク質への結合を介した神経障害を検出する方法
US20240325572A1 (en) * 2021-07-15 2024-10-03 Amydis, Inc. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders
US20260217667A1 (en) * 2023-01-18 2026-07-30 Amydis, Inc. Amyloid targeting agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101371A1 (en) * 2010-10-25 2012-04-26 Steven Roger Verdooner Apparatus and Method For Detecting Amyloid In A Retina in a Diagnosis, Advancement, and Prognosing Of Alzheimer's disease, traumatic brain injury, macular degeneration and a plurality of Neurodegenerative dissorders, and Ocular Diseases
WO2015143185A1 (en) * 2014-03-19 2015-09-24 Amydis Diagnostics Amyloid targeting agents and methods of using the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043013A (en) 1987-12-30 1991-08-27 Milliken Research Corporation Washable ink compositions
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6541454B1 (en) 1995-04-04 2003-04-01 Yissum Research Development Company Of The Hebrew University Jerusalem Phosphonates, biphosphonates and pharmaceutical compositions containing them
US6048662A (en) 1998-12-15 2000-04-11 Bruhnke; John D. Antireflective coatings comprising poly(oxyalkylene) colorants
DE10047237A1 (de) 2000-09-23 2002-04-11 Physoptics Opto Electronic Gmb System zur Aufnahme des Netzhautreflexbildes
EP1431280A1 (en) 2001-08-29 2004-06-23 Kyowa Hakko Kogyo Co., Ltd Aryl sulfamate derivatives
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
ATE525664T1 (de) 2004-11-22 2011-10-15 Abbott Medical Optics Inc Copolymerisierbare methin- und anthrachinon- verbindungen und artikel damit
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP2008013446A (ja) 2006-07-03 2008-01-24 Neugen Pharma:Kk 酸化ストレスによる細胞変性を分子背景とする難治性疾患の治療または予防剤
US20090191193A1 (en) 2006-08-02 2009-07-30 Temple University-Of The Commonwealth System Of Higher Education Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
WO2010033861A1 (en) 2008-09-18 2010-03-25 Cedars-Sinai Medical Center Optical method for the detection of alzheimer's disease
WO2011056958A2 (en) 2009-11-06 2011-05-12 Adlyfe, Inc. Detection and treatment of traumatic brain injury
ES2546063T3 (es) 2009-12-10 2015-09-18 The Regents Of The University Of California Agentes de enlace a amiloides
CN102115429B (zh) 2010-01-06 2013-02-27 中国科学院上海药物研究所 (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途
KR101194337B1 (ko) 2010-07-14 2012-10-24 웅진코웨이주식회사 레티노이드 유도체 및 그를 포함하는 화장료 조성물
EP2605694B1 (en) 2010-08-16 2021-10-27 Cognoptix, Inc. Method for detecting amyloid proteins
CA2815960C (en) 2010-10-29 2019-01-22 Clino Ltd. Tau imaging probe
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
EP3068283A1 (en) 2013-11-12 2016-09-21 Cognoptix, Inc. Method for measuring fluorescence in ocular tissue
US9605315B2 (en) * 2014-03-26 2017-03-28 The University Of Montana Detection of traumatic brain injury
WO2015188142A1 (en) * 2014-06-05 2015-12-10 Cedars-Sinai Medical Center Diagnosis and monitoring of traumatic brain injury by imaging retinal abnormalities
EP3191107A2 (en) 2014-09-12 2017-07-19 Amydis Diagnostics, Inc. In vitro compositions comprising human sample and amyloid targeting agent
EP3702786A1 (en) * 2014-10-06 2020-09-02 Université de Genève Markers and their use in brain injury
WO2017004560A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
JP7029718B2 (ja) 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
AU2019372432B2 (en) 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders
JP7591040B2 (ja) 2019-09-18 2024-11-27 アミディス, インコーポレイテッド リン酸化タウタンパク質への結合を介した神経障害を検出する方法
US20240165274A1 (en) 2021-03-12 2024-05-23 Amydis, Inc. Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein
US20240325572A1 (en) 2021-07-15 2024-10-03 Amydis, Inc. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders
US20260217667A1 (en) 2023-01-18 2026-07-30 Amydis, Inc. Amyloid targeting agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101371A1 (en) * 2010-10-25 2012-04-26 Steven Roger Verdooner Apparatus and Method For Detecting Amyloid In A Retina in a Diagnosis, Advancement, and Prognosing Of Alzheimer's disease, traumatic brain injury, macular degeneration and a plurality of Neurodegenerative dissorders, and Ocular Diseases
WO2015143185A1 (en) * 2014-03-19 2015-09-24 Amydis Diagnostics Amyloid targeting agents and methods of using the same

Also Published As

Publication number Publication date
MA52796A (fr) 2021-04-14
JP7583895B2 (ja) 2024-11-14
CN112424606A (zh) 2021-02-26
EP3803416A4 (en) 2022-05-18
JP2024028695A (ja) 2024-03-05
JP2025016675A (ja) 2025-02-04
EP3803416A1 (en) 2021-04-14
US20260207789A1 (en) 2026-07-23
CN119985995A (zh) 2025-05-13
US20210369873A1 (en) 2021-12-02
JP2021525875A (ja) 2021-09-27
CN112424606B (zh) 2025-01-14
AU2019279001A1 (en) 2020-12-03
WO2019232422A1 (en) 2019-12-05
CN112424606B9 (zh) 2025-03-07
US12478693B2 (en) 2025-11-25
CA3100700A1 (en) 2019-12-05
JP7381500B2 (ja) 2023-11-15

Similar Documents

Publication Publication Date Title
JP7583895B2 (ja) 外傷性脳損傷を検出するための組成物および方法
JP7664201B2 (ja) アミロイド標的剤及びその使用方法
JP2018141000A (ja) 白金化合物、組成物、及びそれらの使用
BR112019020691A2 (pt) Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
JP2024177285A (ja) リン酸化タウタンパク質への結合を介した神経障害を検出する方法
AU2019372432B2 (en) Phosphate compounds for detecting neurological disorders
KR20220079546A (ko) 간질 치료 방법
CA2464471C (en) Method of treating depression with delta receptor agonist compounds
WO2024155678A1 (en) Amyloid targeting agents
EP2588109A1 (en) Use of kynurenic acid amide derivatives for the treatment of huntington's disease
AU2022234434A1 (en) Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein
AU2022340700A1 (en) Methods of treatment using bcn057, bcn077 and analogs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)